NCT07374731 Identification of Biomarkers of Risk for Pre-neoplastic and Neoplastic Lesions for the Development of Gastric Cancer
| NCT ID | NCT07374731 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centro di Riferimento Oncologico - Aviano |
| Condition | Gastric Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 192 participants |
| Start Date | 2025-05-21 |
| Primary Completion | 2027-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 192 participants in total. It began in 2025-05-21 with a primary completion date of 2027-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Investigator propose the implementation of circulating biomarker monitoring, focusing on molecules related to the progression of gastric atrophy and/or associated with gastric cancer. Monitoring these biomarkers will provide gastroenterologists with timely information on individuals at risk and, if values worsen during follow-up, will alert physicians observing these patients to evaluate them. This monitoring will be offered to individuals who contact the IBO (Immunopatologia e Biomarcatori Oncologici) Unit at CRO (Centro di Riferimento Oncologico) in Aviano requesting an assessment of gastric function through pepsinogen and G17 gastrin level testing. Monitoring these biomarkers will provide a dynamic analysis of patients' gastric status, allowing for timely intervention in case of deviations from normal values. This proactive approach is important for the preventive management of gastric diseases, particularly for the diagnosis and monitoring of gastric atrophy and gastric cancer. The IBO unit of the CRO in Aviano, together with the pathological anatomy and clinical units of gastroenterology, medical oncology, and surgery, will play a role in coordinating and implementing this monitoring program, thus contributing to the promotion of gastric health and the prevention of associated diseases.
Eligibility Criteria
Inclusion Criteria: * Aged over 18; * Ability to understand, accept, and sign the informed consent form for the study; * Ability to understand, accept, and sign the consent form for data processing; * Ability to understand, accept, and sign the consent form for the collection of a serum sample for research purposes; * Patients who are fasting and have requested a pepsinogen test or gastroscopy, or who have gastric cancer prior to treatment; * Subjects who are fasting and have suspected pre-neoplastic/neoplastic gastric lesions or who have requested a pepsinogen test and for whom endoscopic examination data are available. Exclusion Criteria: * Patients under the age of 18 * Pregnant women * Patients with a coexisting or previous diagnosis of another malignant neoplasm in the last 5 years * Patients unable to understand, accept, and sign the consent form for data processing
Contact & Investigator
Valli De Re
PRINCIPAL INVESTIGATOR
Centro di Riferimento Oncologico
Frequently Asked Questions
Who can join the NCT07374731 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07374731 currently recruiting?
Yes, NCT07374731 is actively recruiting participants. Contact the research team at vdere@cro.it for enrollment information.
Where is the NCT07374731 trial being conducted?
This trial is being conducted at Aviano, Italy.
Who is sponsoring the NCT07374731 clinical trial?
NCT07374731 is sponsored by Centro di Riferimento Oncologico - Aviano. The principal investigator is Valli De Re at Centro di Riferimento Oncologico. The trial plans to enroll 192 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.